Home
Search

Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
BIO Comments to the USPTO’s MAY 10, 2024 Proposed…
BIO submitted these comments in response to the United States Patent and Trademark Office’s May 10, 2024, Notice of Proposed Rulemaking regarding Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting.
Learn more
Comments of the Biotechnology Innovation…
On behalf of its member organizations, Biotechnology Innovation Organization (“BIO”) respectfully submits this Comment in response to the United States Patent and Trademark Office’s (the “Patent Office” or “PTO”) February 13, 2024 Request for…
Learn more
BIO Comments to FWS on Use of GMOs on National…
BIO comments on a proposed rule to restrict planting of GE organisms on national wildlife refuge lands. 
Learn more
All Letters, Testimony & Comments
  • Show All
Search
Results
Sarbanes-Oxley in Financial Services Compromise: Sarbanes-Oxley 404(b) Legislative Text in the Wall Street Reform and Consumer Protection Act of 2009
March 10, 2016
BIO advocated for a provision in financial services reform that would ease regulatory burdens for small public biotechnology companies.
IFRS Roadmap: SEC requests comments on U.S. conversion to a set of global accounting standards
March 10, 2016
BIO provides comment letter to SEC generally supporting the IFRS roadmap while maintaining safeguards for emerging companies during transition.
Sarbanes Oxley 404(b) recommendations made by the 2009 Government-Business Forum on Small Business Capital Formation
March 10, 2016
The 2009 Government-Business Forum on Small Business Capital Formation recommended a permanent exemption for small companies from Section 404(b) of Sarbanes-Oxley. Additionally, they recommended that the SEC increase the public float threshold for…
Cures Acceleration Network: BIO Strongly Supports the CAN Program
March 10, 2016
Implementation of CAN will help NIH-funded researchers bridge the precarious gap between basic research and the eventual development of new cures and treatments for many of the diseases we face today.
Letter to the Honorable John Carey
March 10, 2016
Letter to the Honorable John Carey, Chairman of the Senate Committee on Finance and Financial Institutions in Ohio from BIO, regarding House Bill 66.
BIO Testimony regarding Oregan Senate Bill 570
March 10, 2016
Testimony to the Oregon Senate Environment & Land Use Committee regarding The Oregon Genetically Engineered Pharmaceutical and Industrial Crop Act.
Letter to Governor Deval Patrick
March 10, 2016
BIO letter to Governor Deval Patrick of Massachusetts regarding concerns about Senate Bill 2863.
Questions for the District of Columbia Board of Pharmacy for the drafting of SafeRx
March 10, 2016
Frequently Asked Questions Document
Clinical Trials: Review of the Declaration of Helsinki
March 10, 2016
BIO’s comments on the World Medical Association’s (WMA’s) Declaration of Helsinki.
Clinical Trials: ICTRP guidelines
March 10, 2016
BIO urges the ICTRP to focus on developing a procedure that would address the need to balance the incentive to innovate with the need to provide patients and health care providers with the information they need in order to assess the availability…